Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Feb;45(2):433-8.
doi: 10.1128/AAC.45.2.433-438.2001.

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae

J M Blondeau  1 , X Zhao, G Hansen, K Drlica
Affiliations

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae

J M Blondeau et al. Antimicrob Agents Chemother. 2001 Feb.

Abstract

The mutant prevention concentration (MPC) represents a threshold above which the selective proliferation of resistant mutants is expected to occur only rarely. A provisional MPC (MPC(pr)) was defined and measured for five fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Based on their potential for restricting the selection of resistant mutants, the five fluoroquinolones, in descending order, were found to be moxifloxacin > trovafloxacin > gatifloxacin > grepafloxacin > levofloxacin. For several compounds, 90% of about 90 clinical isolates that lacked a known resistance mutation had a value of MPC(pr) that was close to or below the serum levels that could be attained with a dosing regimen recommended by the manufacturers. Since MPC(pr) overestimates MPC, these data identify moxifloxacin and gatifloxacin as good candidates for determining whether MPC(pr) can be used as a guide for choosing and eventually administering fluoroquinolones to significantly reduce the development of resistance.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Distribution of S. pneumoniae isolates with respect to MPCpr. MPCpr was determined for each isolate by the agar dilution method. White areas of bars represent isolates containing parC mutations known to confer resistance; shaded regions represent isolates containing parC mutations that have not been demonstrated by genetic tests to confer quinolone resistance; solid regions represent unsequenced isolates. Dashed line is for alignment of panels. Panels: A, moxifloxacin; B, gatifloxacin; C, trovafloxacin; D, grepafloxacin; and E, levofloxacin.
See this image and copyright information in PMC

References

    1. Bingen E, Lambert-Zechovsky N, Mariani-Kurkdjian P, Doit C, Aujard Y, Fournerie F, Mathieu H. Bacterial counts in cerebrospinal fluid of children with meningitis. Eur J Clin Microbiol Infect Dis. 1990;9:278–281. - PubMed
    1. Blaser J, Stone B, Groner M, Zinner S. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987;31:1054–1060. - PMC - PubMed
    1. Blondeau J. A review of clinical trials with fluoroquinolones with an emphasis on new agents. Expert Opin Investig Drugs. 2000;9:383–413. - PubMed
    1. Chen D K, McGeer A, DeAzavedo J C, Low D E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999;341:233–239. - PubMed
    1. Dong Y, Zhao X, Domagala J, Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother. 1999;43:1756–1758. - PMC - PubMed

Publication types

MeSH terms